Study identifier:D4325C00007
ClinicalTrials.gov identifier:NCT05967806
EudraCT identifier:N/A
CTIS identifier:N/A
An international, non-randomised, non-interventional, multicentre study to identify and characterise patients with CKD and high proteinuria for possible participation in future renal clinical studies.
Renal disease
N/A
No
-
All
2575
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2025 by AstraZeneca
AstraZeneca
-
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
Location
Location
Waterloo, Canada
Location
London, Canada
Location
Guangdong, China
Location
Beijing, China
Location
Zhejiang, China
Location
Hunan, China
Location
Hubei, China
Location
Sichuan, China
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.